The antipsychotic drug pimozide inhibits IgE-mediated mast cell degranulation and migration
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 84, 106500
- https://doi.org/10.1016/j.intimp.2020.106500
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
This publication has 48 references indexed in Scilit:
- Hypersensitivity Reactions to CorticosteroidsClinical Reviews in Allergy & Immunology, 2013
- The interaction between Lyn and FcεRIβ is indispensable for FcεRI-mediated human mast cell activationAllergy, 2012
- The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsGenes & Cancer, 2012
- Cytoskeleton in Mast Cell SignalingFrontiers in Immunology, 2012
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsBlood, 2011
- Histamine and its receptorsBritish Journal of Pharmacology, 2006
- Molecular and cellular targets of anti‐IgE antibodiesAllergy, 2005
- Neutrophil recruitment in mast cell-dependent inflammation: inhibitory mechanisms of glucocorticoidsInflammation Research, 2004
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozideBiological Psychiatry, 1986